ReviewPediatric nephrology (Berlin, Germany)2011
Wilms tumor--a renal stem cell malignancy?
Review in Pediatric nephrology (Berlin, Germany), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- DLX6-AS1 promotes the progression of Wilms tumor by sponging miR-195-5p to upregulate KIF23 in Wilms tumor cells.Discover oncology · 2026Article
- Article
- Modeling high-risk Wilms tumors enables the discovery of therapeutic vulnerability.Cell reports. Medicine · 2024Article
- Study of cellular heterogeneity and differential dynamics of autophagy in human embryonic kidney development by single-cell RNA sequencing.Cancer cell international · 2021Article
- Wilms tumor-suppressing peptide inhibits proliferation and induces apoptosis of Wilms tumor cells in vitro and in vivo.Journal of cancer research and clinical oncology · 2019Article
- NCAM1/FGF module serves as a putative pleuropulmonary blastoma therapeutic target.Oncogenesis · 2019Article
- Investigating the dysfunctional pathogenesis of Wilms' tumor through a multidimensional integration strategy.Annals of translational medicine · 2019Article
- Cancer Stem Cells are Regulated by STAT3 Signalling in Wilms Tumour.Journal of Cancer · 2018Article
- HMGA2 overexpression predicts relapse susceptibility of blastemal Wilms tumor patients.Oncotarget · 2017Article
- Induced Pluripotent Stem Cells Reduce Progression of Experimental Chronic Kidney Disease but Develop Wilms' Tumors.Stem cells international · 2017Article
- Association ofOncology letters · 2016Article
- Dissecting Stages of Human Kidney Development and Tumorigenesis with Surface Markers Affords Simple Prospective Purification of Nephron Stem Cells.Scientific reports · 2016Article
- Dermatoglyphics in kidney diseases: a review.SpringerPlus · 2016Review
- The yin and yang of kidney development and Wilms' tumors.Genes & development · 2015Review
- Energy metabolism in neuroblastoma and Wilms tumor.Translational pediatrics · 2015Review
- Treating childhood cancer in Rwanda: the nephroblastoma example.The Pan African medical journal · 2015Article
- SIX2 Effects on Wilms Tumor Biology.Translational oncology · 2014Article
- Wilms' tumor blastemal stem cells dedifferentiate to propagate the tumor bulk.Stem cell reports · 2014Article
- Targeted therapy aimed at cancer stem cells: Wilms' tumor as an example.Pediatric nephrology (Berlin, Germany) · 2014Review
- Renal progenitors and childhood: from development to disorders.Pediatric nephrology (Berlin, Germany) · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Wilms' tumor (WT; nephroblastoma) is the most common pediatric renal malignancy and rated fourth in overall incidence among childhood cancers. It is viewed as a prototype of differentiation failure in human neoplasia as it recapitulates the histology of the nephrogenic zone of the growing fetal kidney. The cellular origin of WT is unclear. However, recent genomic, genetic and epigenetic studies point to an early renal stem/progenitor cell that undergoes malignant transformation as the source for WT. In this context, classical WT shares genes and pathways activated in progenitors committed to the renal lineage. However, direct proof and characterization of the WT initiating cell have remained elusive. Novel methodologies recently adopted from the cancer stem cell scientific field, including the analysis of sorted single human tumor cells, have been applied to WT. These have enabled the identification of cell sub-populations that show similarities-in terms of molecular marker expression-to human fetal kidney progenitors and are, therefore, likely to be derivatives of the same lineage. Further elucidation of the WT cancer stem cell or the cell of origin in human tumors and in transgenic mouse models that generate murine tumors may not only provide novel therapeutic targets but also shed light on the normal kidney stem cell.
Indexed as
Identifiers
21499773What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.